Collegium Pharmaceutical, Inc. (COLL)

NASDAQ: COLL · USD

$23.2

+0.19 (+0.8%)· Recorded snapshot

Market cap	755M
Revenue (ttm)	808.2M
Net income (ttm)	47.9M
EPS (ttm)	$1.41
Shares out	32.6M
P/E (trailing)	16.5x
P/E (forward)	3.3x
Volume	308,756
Beta	0.73

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 808.2M
Net income (ttm): 47.9M
EPS (ttm): $1.41
P/E (trailing): 16.5x
P/E (forward): 3.3x
Market cap: 755M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E3.3

P25 13.4P50 20.2P75 35.7

Trailing P/E16.5

P25 15.4P50 25.8P75 43.5

ROE17.6

P25 -113.8P50 -46.5P75 -0.9

ROIC9.5

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All COLL indicators

Market & fundamental data

Available fields

259

Groups with data

Currency

USD

Showing 259 of 259 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001267565
Company name	Collegium Pharmaceutical, Inc.
Country	United States
Country code	US
CUSIP number	19459J104
Earnings date	2026-11-05
Earnings time	bmo
Employees	423
Employees change	66
Employees growth	18.49%
Enterprise value	$1.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2002
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2015-05-07
Is primary listing	Yes
Is SPAC	No
ISIN number	US19459J1043
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$755M
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$23.19
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	COLL
U.S. state	Massachusetts
Website	https://www.collegiumpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	2.91x
Average P/E ratio (3Y)	23.91x
Average P/E ratio (5Y)	21.24x
Earnings yield	6.06%
EV/Earnings	38.39x
EV/EBIT	10.72x
EV/EBITDA	4.54x
EV/FCF	5.6x
EV/Sales	2.28x
FCF / EV yield	17.84%
FCF yield	43.7%
Forward EV/Sales	2.19x
Forward P/E	3.27x
Forward P/S	0.89x
Graham number	17.42096
Graham upside	-24.5%
Industry forward P/E	13.86x
Industry P/E	173.47x
Lynch fair value	$7.03
Lynch upside	-69.55%
P/(FCF - SBC) ratio	2.65x
P/(OCF - SBC) ratio	2.64x
P/B ratio	2.4x
P/E ratio	16.5x
P/FCF ratio	2.29x
P/OCF ratio	2.28x
P/S ratio	0.93x
PEG ratio	0.65x
Price/EBITDA ratio	1.85x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21.24%
EBITDA margin	50.14%
Effective tax rate	38.32%
FCF margin	40.62%
Gross margin	89.45%
Operating margin	21.24%
Pretax margin	9.61%
Profit margin	5.93%
Profit per employee	$113,274
Profitable years	3
Revenue per employee	$1.9M
ROA	5.75%
ROA (5Y)	6.05%
ROCE	11.1%
ROE	17.61%
ROE (5Y)	21.04%
ROIC	9.54%
ROIC (5Y)	12.84%
SBC / revenue	5.56%
Tax / revenue	3.68%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	32.73%
EPS growth 5Y	-13.21%
EPS growth years	0
FCF growth	62.67%
FCF growth (Q)	-2.14%
FCF growth (QoQ)	24.6%
FCF growth 3Y	11.76%
FCF growth 5Y	26.38%
Gross profit growth	16.85%
Gross profit growth (Q)	7.75%
Gross profit growth 3Y	16.61%
Gross profit growth 5Y	22.18%
Net income growth	32.1%
Net income growth 5Y	-14.8%
Net income growth years	0
OCF growth	62.14%
OCF growth (Q)	-1.54%
OCF growth (QoQ)	24.88%
OCF growth 3Y	11.74%
OCF growth 5Y	25.29%
Operating income growth	4.45%
Operating income growth (Q)	-69.98%
Operating income growth 3Y	5.33%
Operating income growth 5Y	18.9%
Revenue growth	14.31%
Revenue growth (Q)	6.32%
Revenue growth (QoQ)	3.29%
Revenue growth 3Y	14.6%
Revenue growth 5Y	19.9%
Revenue growth quarters	17
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.6M
Depreciation and amortization	$233.6M
EBIT	$171.7M
EBITDA	$405.3M
EPS	$1.41
FCF per share	$10.08
Financing cash flow	$234.1M
Free cash flow	$328.3M
Free cash flow minus SBC	$283.4M
Gross profit	$722.9M
Income taxes	$29.8M
Investing cash flow	$-551.9M
Net borrowing	$246.9M
Net cash flow	$12.1M
Net income	$47.9M
Operating cash flow minus SBC	$285M
Operating income	$171.7M
Revenue	$808.2M
Stock-based compensation	$44.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.99
Book value per share	$9.60
Debt / EBITDA	2.95
Debt / equity	3.9
Debt / FCF	3.71
Goodwill	$190.2M
Interest coverage	2.25
Long-term assets	$1.5B
Long-term liabilities	$1.2B
Net cash (debt)	$-1.1B
Net cash / market cap	-144.89%
Net debt / EBITDA	2.69
Net debt / equity	3.49
Net debt / FCF	3.32
Piotroski F-Score	5
Property, plant and equipment	$14.4M
Shareholders' equity	$311.9M
Tangible book value	$-1.1B
Tangible book value per share	$-32.75
Total assets	$2.1B
Total cash	$129.5M
Total debt	$1.2B
Total liabilities	$1.8B
WACC	5.55%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.43
Current assets	$608M
Current liabilities	$589.9M
Current ratio	1.03
Inventory turnover	1.13
Net working capital	$-54.8M
Quick ratio	0.7
Working capital	$18.2M
Working capital turnover	15.73

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	9.08%
Dividend yield	0%
Shareholder yield	9.08%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	55.01%
10Y return CAGR	4.48%
10Y total return	55.01%
150-day SMA	$30.46
1D price change	0.83%
1M price change	2.93%
1M total return	2.93%
1W price change	1.2%
1W total return	1.2%
1Y price change	-33.39%
1Y return CAGR	-33.41%
1Y total return	-33.39%
20-day SMA	$22.56
200-day SMA	$33.47
3M price change	-34.71%
3M total return	-34.71%
3Y price change	9.59%
3Y return CAGR	3.1%
3Y total return	9.59%
50-day SMA	$23.47
50-day SMA vs 200-day SMA	50under200
52-week high	$50.79
52-week high date	2025-12-29
52-week low	$21.43
52-week low date	2026-10-01
5Y price change	11.98%
5Y return CAGR	2.29%
5Y total return	11.98%
6M price change	-29.26%
6M total return	-29.26%
All-time high	$50.79
All-time high date	2025-12-29
All-time low	$7.37
All-time low date	2017-05-09
Average true range (ATR)	$0.83
Average volume	667.2K
Beta (1Y)	0.12
Beta (2Y)	0.33
Beta (5Y)	0.73
Change from 52-week high	-54.34%
Change from 52-week low	8.21%
Change from all-time high	-54.34%
Change from all-time low	214.65%
Change from open	1.67%
Day's gap	-0.83%
Dollar volume	$7.2M
High price	$23.26
Low price	$22.67
Monthly RSI	38.8
Open price	$22.81
Position in 52-week range	88.14%
Premarket change	-2%
Premarket close	$23.00
Premarket price	$22.54
Premarket volume	2.3K
Previous close	$23.00
Price vs 150-day SMA	-23.87%
Price vs 20-day SMA	2.79%
Price vs 200-day SMA	-30.71%
Price vs 50-day SMA	-1.18%
Relative volume	0.47
RSI	51.55
Sharpe ratio	-0.79
Sharpe ratio (3Y)	0.18
Sharpe ratio (5Y)	0.15
Sortino ratio	-0.94
Sortino ratio (3Y)	0.39
Sortino ratio (5Y)	0.36
Volume	308.8K
Weekly RSI	31.14
YTD price change	-49.91%
YTD total return	-49.91%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	29.8M
Float percentage	91.44%
Shares change (QoQ)	-18.98%
Shares change (YoY)	-9.08%
Shares held by insiders	1.12%
Shares held by institutions	119.39%
Shares outstanding	32.6M
Short % of float	18.06%
Short % of shares	16.51%
Short ratio	5.9 days

Deeper analysis on COLL

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this COLL report

Is a complete COLL research report available?

No complete published report is available for Collegium Pharmaceutical, Inc. (COLL) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Collegium Pharmaceutical, Inc. (COLL)

Price

Financial snapshot

Fair-value bridge

Latest news · COLL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All COLL indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on COLL

Frequently asked questions